- Home
- MRNA vs VTRS Comparison
MRNA vs VTRS Comparison
Compare MRNA & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNA
- VTRS
- Stock Information
- Founded
- MRNA 2010
- VTRS 1961
- Country
- MRNA United States
- VTRS United States
- Employees
- MRNA N/A
- VTRS N/A
- Industry
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- MRNA Health Care
- VTRS Health Care
- Exchange
- MRNA Nasdaq
- VTRS Nasdaq
- Market Cap
- MRNA 10.3B
- VTRS 10.6B
- IPO Year
- MRNA 2018
- VTRS N/A
- Fundamental
- Price
- MRNA $30.28
- VTRS $9.34
- Analyst Decision
- MRNA Hold
- VTRS Hold
- Analyst Count
- MRNA 19
- VTRS 5
- Target Price
- MRNA $48.13
- VTRS $10.40
- AVG Volume (30 Days)
- MRNA 9.3M
- VTRS 12.4M
- Earning Date
- MRNA 07-31-2025
- VTRS 08-07-2025
- Dividend Yield
- MRNA N/A
- VTRS 5.14%
- EPS Growth
- MRNA N/A
- VTRS N/A
- EPS
- MRNA N/A
- VTRS N/A
- Revenue
- MRNA $3,177,000,000.00
- VTRS $14,330,200,000.00
- Revenue This Year
- MRNA N/A
- VTRS N/A
- Revenue Next Year
- MRNA $9.70
- VTRS $1.85
- P/E Ratio
- MRNA N/A
- VTRS N/A
- Revenue Growth
- MRNA N/A
- VTRS N/A
- 52 Week Low
- MRNA $23.15
- VTRS $6.85
- 52 Week High
- MRNA $129.39
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- MRNA 67.06
- VTRS 62.77
- Support Level
- MRNA $26.81
- VTRS $8.88
- Resistance Level
- MRNA $28.24
- VTRS $9.16
- Average True Range (ATR)
- MRNA 1.24
- VTRS 0.23
- MACD
- MRNA 0.34
- VTRS 0.03
- Stochastic Oscillator
- MRNA 93.38
- VTRS 91.28
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.